178 related articles for article (PubMed ID: 34590032)
1. Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma.
Kim RY; Mitra N; Bagley SJ; Marmarelis ME; Haas AR; Rendle KA; Vachani A
JTO Clin Res Rep; 2021 Jun; 2(6):100188. PubMed ID: 34590032
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
Kim RY; Li Y; Marmarelis ME; Vachani A
Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
[TBL] [Abstract][Full Text] [Related]
3. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
[TBL] [Abstract][Full Text] [Related]
4. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.
Brockwell NK; Alamgeer M; Kumar B; Rivalland G; John T; Parker BS
Transl Lung Cancer Res; 2020 Jun; 9(3):639-645. PubMed ID: 32676326
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases.
Barbieri PG; Consonni D; Schneider M
Tumori; 2022 Feb; 108(1):26-32. PubMed ID: 33719756
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
[TBL] [Abstract][Full Text] [Related]
7. Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.
Assié JB; Crépin F; Grolleau E; Canellas A; Geier M; Grébert-Manuardi A; Akkache N; Renault A; Hauss PA; Sabatini M; Bonnefoy V; Cortot A; Wislez M; Gauvain C; Chouaïd C; Scherpereel A; Monnet I
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326648
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of combined immunotherapy in patients with malignant pleural mesothelioma].
Zhao C; Fei KL; Wan R; Song LP; Xiang PC; Duan JC
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):445-451. PubMed ID: 37188631
[No Abstract] [Full Text] [Related]
9. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
[TBL] [Abstract][Full Text] [Related]
10. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
Cedrés S; Ponce-Aix S; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Gómez-Abecia S; Zucchiatti AC; Sansano I; Enguita AB; Miquel JM; Viaplana C; Dienstmann R; Paz-Ares L; Felip E
Clin Transl Oncol; 2020 Aug; 22(8):1390-1398. PubMed ID: 31916017
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
Cortinovis D; Grosso F; Carlucci L; Zucali PA; Pasello G; Tiseo M; Sperandi F; Hollander L; Galli F; Torri V; Rulli E; Canova S; Maconi A; Bidoli P; Ceresoli GL; D'Incalci M;
Clin Lung Cancer; 2021 Jul; 22(4):361-370.e3. PubMed ID: 32732073
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
Parikh K; Hendriks LEL; Bironzo P; Remon J
Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
[TBL] [Abstract][Full Text] [Related]
13. Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?
Escalon JG; Harrington KA; Plodkowski AJ; Zheng J; Capanu M; Zauderer MG; Rusch VW; Ginsberg MS
J Comput Assist Tomogr; 2018; 42(4):601-606. PubMed ID: 29613986
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
[TBL] [Abstract][Full Text] [Related]
15. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
16. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
[TBL] [Abstract][Full Text] [Related]
17. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
18. The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
Borgeaud M; Kim F; Friedlaender A; Lococo F; Addeo A; Minervini F
J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902544
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Danese MD; Daumont M; Nwokeji E; Gleeson M; Penrod JR; Lubeck D
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1568. PubMed ID: 34698447
[TBL] [Abstract][Full Text] [Related]
20. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
